Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

DNA
(Shutterstock)

Sangamo Therapeutics’ efforts to secure a partnership for ST-920 (isaralgagene civoparvovec), its gene therapy for Fabry disease, should get easier now that the biotech has positive pivotal data supporting a US Food and Drug Administration filing.

Key Takeaways
  • Sangamo unveiled positive data from the pivotal STAAR trial of ST-920 and plans to seek approval for the therapy in Fabry disease in 2026.  

The Richmond, Calif.-based, gene therapy-focused biotech said June 24 that the pivotal Phase I/II STAAR study met the endpoint –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More from Business

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.